{"entity":{"id":"tarebio","kind":"company","name":"TareBio","aka":[],"tldr":"TareBio reads the immune cells already fighting a cancer in a patient's body and works backwards to design a vaccine that makes more of them, in weeks rather than years.","summary":"TareBio's platform designs personalised or population-level vaccines by reading out the immune imprint, the T and B cells already engaged against a disease in the body, and reverse-engineering antigens that activate them, rather than predicting antigens from tumour sequencing alone. The company reports having run the platform end to end and produced a vaccine that cleared tumours in mice. It is a one-person Summer 2026 YC company; the work is preclinical.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/tarebio"},{"label":"Official website","url":"https://tarebio.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine","shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://tarebio.com","stage":"startup","ycBatch":"S26","investors":["y-combinator"],"funding":[]},"route":"/companies/tarebio/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"company":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"}]}}